ATLANTA, GA – – (Newsfile Corp. – July 6, 2021) – – Holzer & Holzer, LLC is investigating whether Provention Bio, Inc. (“Provention” or the “Company”) (NASDAQ: PRVB) complied with federal securities laws. On July 6, 2021, Provention announced the issuance of a Complete Response Letter (“CRL”) by the FDA for the Company’s Biologics License Application (“BLA”) for the drug Teplizumab. Specifically, the FDA noted that a recent study “failed to show Pharmacokinetic comparability” and notified Provention that it must either demonstrate PK compatibility for Teplizumab or provide other data showing why PK compatibility is not necessary. After the Company’s announcement, the price of Provention significantly dropped. If you purchased shares of Provention stock and suffered a loss on that investment, you are encouraged to either contact Corey D. Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.